Grygiel Nancy A. 4
4 · AMGEN INC · Filed Nov 21, 2025
Insider Transaction Report
Form 4
AMGEN INCAMGN
Grygiel Nancy A.
SVP & CCO
Transactions
- Exercise/Conversion
Nqso (Right to Buy)
2025-11-20−1,639→ 0 totalExercise: $162.60From: 2019-05-01Exp: 2027-05-01→ Common Stock (1,639 underlying) - Exercise/Conversion
Common Stock
2025-11-20$177.46/sh+1,500$266,190→ 8,725 total - Sale
Common Stock
2025-11-20$337.26/sh−1,639$552,773→ 7,225 total - Exercise/Conversion
Nqso (Right to Buy)
2025-11-20−1,500→ 1,970 totalExercise: $177.46From: 2020-04-27Exp: 2028-04-27→ Common Stock (1,500 underlying) - Sale
Common Stock
2025-11-20$337.26/sh−1,500$505,894→ 7,225 total - Exercise/Conversion
Common Stock
2025-11-20$162.60/sh+1,639$266,501→ 8,864 total
Holdings
- 104.685(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F2]These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- [F3]These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.